Adam D. Levy
Chief Financial Officer · Acrivon Therapeutics, Inc.
- 2025
- Aug 6, 2026
- 5
Other insiders active in the same stocks
Insiders who reported open-market trades in the last 12 months at the companies Adam D. Levy files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- Peter Blume-Jensen - $117K in ACRV purchases and sales in the last 12 months
- Eric Devroe - $18K in ACRV purchases and sales in the last 12 months
- Mary Miller - $2K in ACRV purchases and sales in the last 12 months
- Erick Gamelin - $804 in ACRV purchases and sales in the last 12 months
- Katharine Peterson - $203 in ACRV purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Adam D. Levy?
Adam D. Levy is a corporate insider, tracked as Chief Financial Officer of Acrivon Therapeutics, Inc. (ACRV). InsiderAlpha holds 5 primary Form 4 filings for them, the earliest from 2025, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Adam D. Levy submitted recently?
1 primary Form 4 filing in the last 90 days, covering 1 company.
Has Adam D. Levy been buying or selling stock?
Recorded transactions: 1 open-market purchase ($15K) and 1 open-market sale ($2K) across all tracked filings.
